She is forty-three. The dress for the dinner is hanging on the back of the bathroom door. The lighting in this particular bathroom has not been flattering since 2019, and she has stopped pretending otherwise. She tilts her chin up. The jawline she had at thirty-five is no longer the jawline she has now. Somewhere between the second child and the third promotion, the architecture of her face quietly relocated. This is the appointment that fills Dr. Jan’s Tuesday afternoons. Th

The new problem in Philippine weight management is not scarcity. It is choice. Four years ago, a woman who wanted medical help losing weight in Manila had a narrow menu and a physician willing to prescribe around it. Then Mounjaro arrived in January 2026, the first dual-action medication of its class, approved here for both obesity and type 2 diabetes, a breadth its American sibling Zepbound does not carry. Wegovy followed in April, the dedicated weight-loss formulation of se

Semaglutide (Ozempic/Wegovy) and Tirzepatide (Mounjaro/Zepbound) have transformed medical weight loss. Patients are achieving remarkable, sustained fat reduction. However, a significant weight loss journey often reveals two aesthetic challenges: stubborn fat pockets that resist the medication, and the crucial need to maintain muscle tone and skin firmness . This leads to the question we hear most often from our successful patients: When is the right time to transition f